Tysabri feels the heat
Executive Summary
Safety evaluation of patients taking Biogen Idec/Elan's multiple sclerosis product Tysabri (natalizumab) remains on track to be completed by "late summer," Elan says. Following a Boston Globe report of a potential fourth case of progressive multifocal leukoencephalopathy, Elan emphasized that there have been only three confirmed cases and two fatalities. In May, FDA said that it will weigh the opinion of patient groups in deciding whether Tysabri should return to market (1"The Pink Sheet" May 16, 2005, p. 12)...
You may also be interested in...
Tysabri Return Depends On Patient Group Input, CDER Deputy Says
FDA will rely on the input of multiple sclerosis patient organizations to help determine the status of Biogen Idec/Elan's Tysabri, Center for Drug Evaluation & Research Acting Deputy Director Douglas Throckmorton told the Stanford Washington Research Group conference May 5
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.